IQVIA Holdings Inc. (IQV)
Health Care2 articles
Price chart
IQVIA Holdings Inc. (IQV) overview
IQVIA provides clinical-research services and healthcare data analytics. It is a member of the S&P 500 and is classified in the Health Care sector — pharmaceutical, biotech, device and managed-care companies.
IQVIA Holdings Inc. trades on the NYSE under the ticker symbol IQV. As of the most recent market data, the stock was priced around $261.19, down 0.21% on the session, giving IQVIA Holdings Inc. a market capitalization of roughly $42.99B.
Over the past 52 weeks, IQV has traded between $154.50 and $265.25. Shares are valued at a trailing price-to-earnings (P/E) ratio of about 32.6, a common gauge of how richly the market prices the company's earnings.
Key statistics
Informational only, not financial advice. Content is AI-generated and may contain errors. How this works.
Why investors watch IQV
As one of the larger companies in the Health Care sector, IQVIA Holdings Inc. is closely followed by investors and often moves with broader trends across pharmaceutical, biotech, device and managed-care companies. Traders watch IQV for earnings reports, analyst rating changes, and headlines that can shift sentiment — each of which is summarized on this page as it breaks.
Market Mood
Latest IQV news
IQVIA (IQV) CEO Sold $26.1 Million Shares as Bookings Hit $3.15B
Ari Bousbib, Chairman and CEO of IQVIA Holdings Inc. (NYSE:IQV), sold about 106,000 shares for proceeds of $26.1 million, according to an SEC Form 4 filing. The shares were sold at a weighted average price of $245.51, slightly below the market close of $247.56 on July 29, 2026. This transaction reduced Bousbib's direct holdings by 11%, but he retains beneficial ownership of 1.4 million shares, including 543,000 shares through the Orohena Trust. This insider sale comes as IQVIA reported record bookings of $3.15 billion, highlighting its robust position in the life sciences industry.
Read More: IQVIA (IQV) CEO Sold $26.1 Million Shares as Bookings Hit $3.15B
IQVIA (IQV) Launches AI Platform to Improve Life Sciences Operations
On March 16, IQVIA Holdings Inc. (IQV) announced the launch of the IQVIA.ai platform, developed in collaboration with Nvidia. The platform aims to enhance operational efficiency in life sciences by integrating healthcare-grade AI with Nvidia's technology. At launch, 19 of the top 20 pharmaceutical companies were reported to be incorporating IQVIA's intelligent agents into their operations. Further enhancements and additional agents are scheduled for release in Q4 2026, indicating the company's commitment to expanding its capabilities in the healthcare space.
Read More: IQVIA (IQV) Launches AI Platform to Improve Life Sciences OperationsMore Health Care stocks
Frequently asked questions
Is IQVIA Holdings Inc. in the S&P 500?
Yes. IQVIA Holdings Inc. (IQV) is a member of the S&P 500 index, classified in the Health Care sector.
What sector is IQV in?
IQVIA Holdings Inc. is classified in the Health Care sector of the S&P 500 — pharmaceutical, biotech, device and managed-care companies.
Where can I find the latest IQV news?
This page collects recent IQVIA Holdings Inc. (IQV) news and market analysis, each article summarized by AI and tagged with bullish, bearish, or neutral sentiment.
What is IQVIA Holdings Inc.'s stock price?
As of the most recent market data, IQVIA Holdings Inc. (IQV) traded at approximately $261.19. Prices move throughout the trading day, so this reflects the latest available quote rather than a live price.
What is IQVIA Holdings Inc.'s market cap?
IQVIA Holdings Inc. has a market capitalization of roughly $42.99B, based on its most recent share price and shares outstanding.
What is IQV's P/E ratio?
IQV trades at a trailing price-to-earnings ratio of about 32.6. The P/E ratio compares a company's share price to its earnings per share.